Plain-English translation of NCT06927739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can reduce inflammation in the arteries of the heart for people who have survived a heart attack. Researchers believe that inflammation in these arteries may contribute to future heart problems, and this medication is designed to target that inflammation. You would receive either the active medication at one of two doses or a placebo (a dummy pill) to see if the treatment is safe and effective.
After a heart attack, some people develop ongoing inflammation in their heart arteries, which can increase the risk of future heart problems. Current treatments don't specifically target this inflammation, so this trial is testing whether this medication could fill that gap and help prevent future complications.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo at either a high or low dose. You would take your assigned treatment and attend study visits where doctors will monitor your heart health, check for any side effects, and run blood tests. There is also an optional additional visit at day 14 where you could have extra blood work done. The study involves 240 people total and will track your progress to see if the medication is safe and helps reduce heart artery inflammation.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States